Analyst Ratings For Premaitha Health PLC (LON:NIPT)
Today, FinnCap reiterated its Corporate rating on Premaitha Health PLC (LON:NIPT) with a price target of GBX 18.
There are 1 buy rating on the stock.
The current consensus rating on Premaitha Health PLC (LON:NIPT) is Buy (Score: 3.00) with a consensus target price of GBX 21 per share, a potential .
Some recent analyst ratings include
- 2/20/2017-FinnCap Reiterated Rating of Corporate.
- 7/4/2016-Panmure Gordon Reiterated Rating of Buy.
About Premaitha Health PLC (LON:NIPT)
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome), Trisomy 13 (Patau’s syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time. The Company operates in the United Kingdom and Rest of the World.
Recent Trading Activity for Premaitha Health PLC (LON:NIPT)
Shares of Premaitha Health PLC closed the previous trading session at 11.04 up +0.41 3.91% with 0 shares trading hands.
